1983
DOI: 10.1093/eurheartj/4.suppl_a.61
|View full text |Cite
|
Sign up to set email alerts
|

The cardiac glycoside-receptor system in the human heart

Abstract: Specific binding sites have been demonstrated to exist in the heart for several drugs and hormones such as beta-blocking agents, cardiac glycosides, catecholamines, insulin, glucagon and acetylcholine. The specific binding sites for cardiac glycosides in the human heart have certain properties which make it likely that they are the pharmacological receptors for the therapeutic and toxic actions of digitalis glycosides: they are located in the cell membrane and bind cardioactive steroids reversibly with high af… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

2
5
0

Year Published

1983
1983
2000
2000

Publication Types

Select...
5
3

Relationship

1
7

Authors

Journals

citations
Cited by 27 publications
(7 citation statements)
references
References 0 publications
2
5
0
Order By: Relevance
“…The number of binding sites is decreased by 50 %. This might be a reflection of membrane disappearance, following membrane disruption and cell lysis, as has been explained for the decrease in ouabain binding sites observed in the area of lesion after myocardial infarction (7). Hypertrophy is also associated with acute rejection, and results in lower binding sites capacity and may explain our results.…”
Section: Discussionsupporting
confidence: 63%
See 1 more Smart Citation
“…The number of binding sites is decreased by 50 %. This might be a reflection of membrane disappearance, following membrane disruption and cell lysis, as has been explained for the decrease in ouabain binding sites observed in the area of lesion after myocardial infarction (7). Hypertrophy is also associated with acute rejection, and results in lower binding sites capacity and may explain our results.…”
Section: Discussionsupporting
confidence: 63%
“…Pathological states have also been shown to modify digitalis receptor properties. A significant decrease in the number of cardiac ouabain binding sites has been observed in senescent rats, hypothyroid states, myocardial infarction, in an experimental model of hypertension and in diabetic cardiomyopathy (7,9,13,15,19). Indeed, both affinity and binding capacity of low affinity ouabain binding sites were decreased in cardiac hypertrophy (3).…”
Section: Discussionmentioning
confidence: 99%
“…The differences in the ouabain binding kinetics of human Na,K-ATPase isozymes reported in this study may be reflected in studies on human cardiac plasma membranes where the rapid dissociation process described (t1 ⁄2 10 -13 min) (35,48) could correspond to ␣2-␤ complexes (t1 ⁄2 4 -5 min) while the slower process described (t1 ⁄2 39 -75 min) (35,48,49) could correspond to ␣1-␤ and/or ␣3-␤ isozymes (t1 ⁄2 30 -80 min). On the other hand, in human cardiac plasma membranes, only one association rate constant was described ranging from 0.12 ϫ 10 7 -0.7 ϫ 10 7 M Ϫ1 min Ϫ1 (35,49,50).…”
Section: Pharmacological Properties Of Human Nak-atpase Isozymesmentioning
confidence: 76%
“…On the other hand, in human cardiac plasma membranes, only one association rate constant was described ranging from 0.12 ϫ 10 7 -0.7 ϫ 10 7 M Ϫ1 min Ϫ1 (35,49,50). The particular features of ␣2 isozymes concerning the ouabain binding kinetics allow speculations on their pharmacological role during digitalis treatment.…”
Section: Pharmacological Properties Of Human Nak-atpase Isozymesmentioning
confidence: 99%
“…The density of ouabain binding sites varies markedly between different cell types with heart muscle containing about 1,000 binding sites/gin 2 [11], mononuclear leucocytes about 200 binding sites/gm 2 (about 35,000 sites/cell) [4] and erythrocytes about 1-2 binding sites/gm 2 (about 250 sites/ cell) [12]. Of these cells, only the erythrocyte does not possess a nucleus.…”
Section: Discussionmentioning
confidence: 99%